The biotech company will sell notes due 2032, with an option to raise an additional $300 million, days after its stock hit a multi-year high

The biotech company will sell notes due 2032, with an option to raise an additional $300 million, days after its stock hit a multi-year high

Moderna announces a $2 billion convertible senior note offering to fund its oncology business growth and strategically manage debt.